Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of alpelisib + everolimus with or without exemestane in advanced solid tumors and breast cancer
NL-OMON47387Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alpelisib, everolimus and exemestane in breast cancer, islet cell tumor, renal cell carcinoma (RCC) and 1 more (3 arms), sponsored by Novartis. Primary endpoints: Maximum tolerated dose and/or recommended dose for expansion and Safety and tolerability. Started Jan 2014; status: active, not recruiting.
02
Drugs
alpelisibeverolimusexemestane
03
Conditions
breast cancerislet cell tumorrenal cell carcinoma (RCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47387.